Astrazeneca PLC (AZN) stock forecast and price target
Price $184.45 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($184.45)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $10.12 | +121.0% | $63.4B |
| Next fiscal year ends December 31, 2027 | $11.32 | +11.8% | $67.4B |
| Next quarter ends December 31, 2026 | $1.74 | — | $16.6B |
Consensus of the analysts covering Astrazeneca, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.
Our model vs. Wall Street
Analysts see 12.8% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Astrazeneca’s intrinsic value about 38% below today’s market value, and it scores 2.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Astrazeneca stock price target?
The average 12-month target from 12 analysts is $208.07, 12.8% above the current price of $184.45 Targets range from $158.00 to $240.00.
Is Astrazeneca a buy according to analysts?
The consensus rating is “Buy” (2 strong buy, 7 buy, 2 hold, 1 sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Astrazeneca expected to earn?
Analysts expect EPS of $10.12 for the fiscal year ending December 31, 2026 and $11.32 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.